Gene therapies and emerging biomodalities are developing at an unprecedented pace, improving the lives of patients around the world. The high demand for those treatments opens a competitive market in which faster and high-quality cost-effective solutions are a clear advantage. The starting point for advanced therapies is generally DNA in the shape of plasmid DNA (pDNA). GMP requirements from early stage, together with the right tools and analytics providing the highest quality standards for pDNA, will ensure successful downstream applications as AAV, from early clinical development to commercial phase.

Join this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technology and strategy that drive an optimized plasmid production process and supply.


Key learning objectives

  • Learn the current plasmid DNA manufacturing landscape.
  • Discuss key considerations during plasmid production, including design and screening system and processing.
  • Discuss main challenges linked to GMP pDNA production and the impact on different advanced therapy programs.
  • December 8, 2022 @ 2:00 pm
  • Switzerland - VIRTUAL EVENT
Event starts in
  • 02

  • 21

  • 47


Zürich, Switzerland - VIRTUAL EVENT

Contact Form